Cargando…

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV, GSK), indicated for the prevention of herpes zoster (HZ) in adults ≥ 50 years of age, received its first marketing authorization in October 2017. We reviewed the post-marketing spontaneous adverse event (AE) reports submitted to GSK’s world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tavares-Da-Silva, Fernanda, Miranda Co, Maribel, Dessart, Cristophe, Hervé, Caroline, López-Fauqued, Marta, Mahaux, Olivia, Van Holle, Lionel, Stegmann, Jens-Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810355/ http://dx.doi.org/10.1093/ofid/ofz360.2453

Ejemplares similares

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
por: Pirrotta, Paola, et al.
Publicado: (2021)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Post‐marketing monitoring of intussusception after rotavirus vaccination in Japan
por: Bauchau, Vincent, et al.
Publicado: (2015)

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data
por: Huygen, Frank, et al.
Publicado: (2015)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccines
por: Mahaux, Olivia, et al.
Publicado: (2015)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

2776. Decrease in ceftriaxone treatment failure rates for infections caused by inducible AmpC producing Enterobacterales associated with changes in laboratory susceptibility testing reporting
por: Khan, Ayesha, et al.
Publicado: (2023)

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
por: Parikh, Raunak, et al.
Publicado: (2023)

Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019
por: Phakey, Sachin, et al.
Publicado: (2023)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Introduction to “Transforming pregnancy since 1900”()
por: Al-Gailani, Salim, et al.
Publicado: (2014)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Changes in route of hysterectomy in Norway since introduction of robotic approach
por: Johanson, ML, et al.
Publicado: (2021)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series
por: Terheyden, Patrick, et al.
Publicado: (2023)

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2020)

An Introduction to Financial Markets
por: Brandimarte, Paolo
Publicado: (2017)

An introduction to bond markets
por: Choudhry, Moorad
Publicado: (2010)

An introduction to the bond markets
por: Brown, Patrick J
Publicado: (2006)

An introduction to trading in the financial markets: market basics
por: Williams, R Tee
Publicado: (2011)

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

2483. Twelve-Month Immunogenicity and Safety of an Adjuvanted Recombinant Zoster Vaccine in Immunosuppressed Adults Post Renal Transplant: a Phase III Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2018)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
por: Kim, Joon Hyung, et al.
Publicado: (2021)

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
por: Dagnew, Alemnew F, et al.
Publicado: (2018)

Inflation and wage growth since the pandemic()
por: Jordà, Òscar, et al.
Publicado: (2023)

Introduction and events since the last ATLAS Week. Progress REPORTs from the calorimetry
por: CERN. Geneva. Audiovisual Unit
Publicado: (1997)

Palliative care coding practices in Canada since the introduction of guidelines and the HSMR indicator
por: Fekri, Omid, et al.
Publicado: (2015)

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
por: Granger, Emily, et al.
Publicado: (2022)

Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
por: Marti, Sebastian Garcia, et al.
Publicado: (2022)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Statistics of financial markets: an introduction
por: Franke, Jürgen, et al.
Publicado: (2019)

Statistics of financial markets: an introduction
por: Franke, Jürgen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6rr6h23arifhimm4318pdgvkoc